Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$6.58

0.42 (6.82%)

13:46
02/17/17
02/17
13:46
02/17/17
13:46

BioCryst call volume above normal and directionally bullish

Bullish option flow detected in BioCryst with 8,991 calls trading, 3x expected, and implied vol increasing over 13 points to 289.44%. Mar-17 7 calls and Mar-17 5 puts are the most active options, with total volume in those strikes near 8,200 contracts. The Put/Call Ratio is 0.12. Earnings are expected on February 27th.

  • 27

    Feb

BCRX BioCryst
$6.58

0.42 (6.82%)

12/16/16
JMPS
12/16/16
UPGRADE
JMPS
Outperform
BioCryst upgraded to Outperform from Market Perform at JMP Securities
12/16/16
JMPS
12/16/16
UPGRADE
JMPS
Outperform
BioCryst upgraded on drug potential at JMP Securities
As noted earlier, JMP Securities upgraded BioCryst to Outperform from Market Perform. Analyst Liisa Bayko believes that a trial of the company's BCX7353 drug for hereditary angioedema could indicate that the drug is capable of "significantly reducing, and possibly wiping out attacks." Bayko adds that "there is significant enthusiasm in the community for an oral option that can achieve at least a 50% reduction in attack frequency." Bayko thinks that the program has a 40% chance of success and could represent a market opportunity of about $12.9B. Target $10.
02/16/17
LTCO
02/16/17
INITIATION
Target $11
LTCO
Buy
BioCryst initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Christopher James started BioCryst Pharmaceuticals with a Buy rating and $11 price target. The company is poised to become a leading oral drug rare disease company, the analyst contends.
02/16/17
02/16/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Salesforce (CRM) initiated with a Hold at Needham by analyst Scott Berg, who cites decelerating organic revenue growth, a looming sales reorganization, and an operating model not profitable enough at its revenue to drive valuation higher. 2. BioCryst (BCRX) initiated with a Buy at Ladenburg by analyst Christopher James, who thinks the company is poised to become a leading oral drug rare disease company. 3. Seaport Global analyst Josh Sullivan started CACI (CACI) International with a Buy rating and $140 price target. The company has broad exposure to trends in fiscal/defense spending, the analyst contends. 4. Citi analyst Walter Pritchard started OpenText (OTEX) with a Neutral rating and $36 price target, stating that the current valuation already reflects the potential of the ECD acquisition. 5. Albireo Pharma (ALBO) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.